Oculis to Present at the Stifel 2024 Healthcare Conference
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care and sight preservation, has announced its participation in the Stifel 2024 Healthcare Conference. The event will take place on November 18-19, 2024, at the Lotte New York Palace Hotel. Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat on November 18 at 3:35 pm ET. The presentation will be available via live webcast, and the company will conduct one-on-one meetings with investors during the conference. Access to the fireside chat will be provided through Oculis' website under the Investors & Media section.
Oculis Holding AG (Nasdaq: OCS), una societ脿 biofarmaceutica globale focalizzata sulla cura degli occhi e sulla preservazione della vista, ha annunciato la sua partecipazione alla Stifel 2024 Healthcare Conference. L'evento si svolger脿 dal 18 al 19 novembre 2024, presso il Lotte New York Palace Hotel. Sylvia Cheung, Chief Financial Officer, parteciper脿 a una chiacchierata informale il 18 novembre alle 15:35 ET. La presentazione sar脿 disponibile tramite webcast in diretta, e la societ脿 condurr脿 incontri individuali con gli investitori durante la conferenza. L'accesso alla chiacchierata sar脿 fornito tramite il sito web di Oculis nella sezione Investitori e Media.
Oculis Holding AG (Nasdaq: OCS), una empresa biofarmac茅utica global enfocada en el cuidado ocular y la preservaci贸n de la vista, ha anunciado su participaci贸n en la Stifel 2024 Healthcare Conference. El evento se llevar谩 a cabo del 18 al 19 de noviembre de 2024, en el Lotte New York Palace Hotel. Sylvia Cheung, Directora Financiera, participar谩 en una charla informal el 18 de noviembre a las 3:35 pm ET. La presentaci贸n estar谩 disponible a trav茅s de una transmisi贸n en vivo, y la empresa llevar谩 a cabo reuniones uno a uno con inversores durante la conferencia. El acceso a la charla se proporcionar谩 a trav茅s del sitio web de Oculis en la secci贸n de Inversores y Medios.
Oculis Holding AG (Nasdaq: OCS)電� 雸� 瓯搓皶 氚� 鞁滊牓 氤挫〈鞐� 欷戩爯鞚� 霊� 旮�搿滊矊 靸濍鞚橃暯頀� 須岇偓搿�, Stifel 2024 Healthcare Conference鞐� 彀胳棳頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. 鞚� 頄夓偓電� 2024雲� 11鞗� 18鞚茧秬韯� 19鞚缄箤歆� Lotte New York Palace Hotel鞐愳劀 歆勴枆霅╇媹雼�. Sylvia Cheung 斓滉碃 鞛 毂呾瀯鞛愱皜 11鞗� 18鞚� 鞓ろ泟 3:35 ET鞐� 鞚茧寑鞚� 雽�頇旍棎 彀胳劃頃� 鞓堨爼鞛呺媹雼�. 氚滍憸電� 霛检澊敫� 鞗轨簮鞀ろ姼毳� 韱淀暣 鞝滉车霅橂┌, 須岇偓電� 須岇潣 欷戩棎 韴瀽鞛愳檧鞚� 鞚茧寑鞚� 氙疙寘鞚� 歆勴枆頃╇媹雼�. 鞚茧寑鞚� 雽�頇旍棎 雽�頃� 鞝戧芳鞚� Oculis鞚� 鞗轨偓鞚错姼 '韴瀽鞛� 氚� 氙鸽敂鞏�' 靹轨厴鞚� 韱淀暣 鞝滉车霅� 瓴冹瀰雼堧嫟.
Oculis Holding AG (Nasdaq: OCS), une entreprise biopharmaceutique mondiale ax茅e sur les soins oculaires et la pr茅servation de la vue, a annonc茅 sa participation 脿 la Stifel 2024 Healthcare Conference. L'茅v茅nement se d茅roulera les 18 et 19 novembre 2024, au Lotte New York Palace Hotel. Sylvia Cheung, directrice financi猫re, participera 脿 une discussion informelle le 18 novembre 脿 15h35 ET. La pr茅sentation sera disponible par le biais d'une diffusion en direct, et l'entreprise organisera des r茅unions individuelles avec des investisseurs pendant la conf茅rence. L'acc猫s 脿 la discussion sera fourni via le site Web d'Oculis dans la section Investisseurs et M茅dias.
Oculis Holding AG (Nasdaq: OCS), ein globales biopharmazeutisches Unternehmen, das sich auf Augenpflege und den Erhalt des Sehens konzentriert, hat seine Teilnahme an der Stifel 2024 Healthcare Conference angek眉ndigt. Die Veranstaltung findet am 18. und 19. November 2024 im Lotte New York Palace Hotel statt. Sylvia Cheung, Chief Financial Officer, wird am 18. November um 15:35 Uhr ET an einer informellen Gespr盲chsrunde teilnehmen. Die Pr盲sentation wird 眉ber einen Live-Webcast verf眉gbar sein und das Unternehmen wird w盲hrend der Konferenz Einzelgespr盲che mit Investoren f眉hren. Der Zugang zur Gespr盲chsrunde wird 眉ber die Website von Oculis im Bereich Investoren und Medien bereitgestellt.
- None.
- None.
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (鈥淥culis鈥�), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis鈥� management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY.
Sylvia Cheung, Chief Financial Officer of Oculis, will participate in a fireside chat on November 18, 2024 at 3:35 pm ET. A live webcast of the fireside chat will be available .
The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Stifel representative to request meetings. A link to access the fireside chat, when available, will be posted to Oculis website on the page under the Investors & Media section.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis鈥� highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; licaminlimab (OCS-02), a topical biologic anti-TNF伪 eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis鈥� goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit: .
Oculis Contacts
Ms. Sylvia Cheung, CFO
Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
1-212-915-2577
FAQ
When is Oculis (OCS) presenting at the Stifel 2024 Healthcare Conference?
Where can I watch Oculis (OCS) Stifel Conference presentation?
Who will represent Oculis (OCS) at the Stifel 2024 Healthcare Conference?
How can investors meet with Oculis (OCS) management at the Stifel Conference?
